普萘洛尔治疗血管瘤的作用机制及其应用研究分析

• 作 者: 蔡放
• 机 构: 国家知识产权局专利局专利审查协作广东中心,
• 出 处: 生物技术世界
• 发表日期: 2013年11期
• 关键词: 血管瘤 婴幼儿血管瘤 普萘洛尔 内皮细胞 作用机制 血管收缩 一线用药 受体阻滞剂 凋亡 临床试验

血管瘤是最常见与婴幼儿的一种先天性的良性肿瘤,普萘洛尔是一种非选择性的受体阻滞剂。近几年来口服使用普萘洛尔治疗婴幼儿血管瘤获得非常满意的效果。其作用机制可能是使血管收缩,进一步抑制血管的形成,尽快消退瘤体,使内皮细胞发生凋亡。它的疗效以及安全性在临床试验中已经得到初步肯定,其可以作为一线用药治疗血管瘤。

Hemangiomas are a congenital benign tumor that is most common with infants and young children. Propranolol is a nonselective receptor blocker. In recent years, oral administration of propranolol to treat infantile hemangiomas obtained very satisfactory results. Its mechanism of action may be to vasoconstriction, and further inhibit the formation of blood vessels, as soon as possible to eliminate the tumor, so that endothelial cell apoptosis occurs. Its efficacy and safety have been initially confirmed in clinical trials, which can be used as first-line therapy for hemangiomas.